cadrenal.com (CVKD) - Year-over-year earnings per share growth for the last twelve months

Cadrenal Therapeutics - graphic logo of issuer CVKD

Cadrenal Therapeutics (CVKD) currently has no commercial sales, as the asset's value depends on trial results. The quarterly earnings per share growth rate exhibits volatility, with the current value standing at 38.20. The business relies on the development of tecarfarine for kidney patients, while patent protection and stringent regulatory requirements block the emergence of cheap generics for years to come.

Cadrenal Therapeutics Inc. (CVKD) - Earnings per share growth in annualized terms for the last twelve months from 04/28/2023 to 11/17/2026

Analytical breakdowns and data insights for company Cadrenal Therapeutics (CVKD)

Initial company analysis:Cadrenal Therapeutics - CVKD
Flagship merchandise of Cadrenal Therapeutics Inc

Developing nephrology drugs under intense pressure from pharma behemoths leaves Cadrenal Therapeutics (CVKD) dependent on the pace of profit capitalization. The quarterly net income per share trend captures the erosion of the issuer's financial stability, allowing investors to distinguish real growth from the risk of overpayment by analyzing the volatility of the quarterly EPS to assess the company's competitiveness.